300633.SHE SonoScape Medical Corp
- Market cap
- CNY 9.23B
- P/E
- 53.0x
- P/B
- 3.04x
- ROE
- 0.5%
- Dividend yield
- 0.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300633.SHE undervalued?
Graham number300633.SHE trades 167.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SonoScape Medical Corp fundamental analysis
No fundamental analysis for SonoScape Medical Corp yet.
SonoScape Medical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SonoScape Medical Corp
SonoScape Medical Corp., together with its subsidiaries, engages in the research, development, production, and sale of medical diagnosis and treatment equipment in China and internationally. It offers ultrasound medical imaging products comprising trolley and portable color dopplers, B/W ultrasounds, and transducers; endoscopic diagnosis and treatment products consisting of image processors, light sources, gastroenterology and pulmonology products, endoscopic ultrasound, duo…
Full company profileSonoScape Medical Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SonoScape Medical Corp annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 719M | 989M | 1.23B | 1.25B | 1.16B | 1.44B | 1.76B | 2.12B | 2.01B | 2.31B | 2.12B |
| Gross Profit | 464M | 673M | 846M | 809M | 753M | 911M | 1.14B | 1.40B | 1.23B | 1.43B | 1.29B |
| Operating Income | 79.2M | 208M | 272M | 107M | -44.2M | 216M | 382M | 475M | 122M | 184M | 54.5M |
| EBITDA | 90.3M | 200M | 269M | 122M | 171M | 248M | 357M | 508M | 164M | 271M | 3.66M |
| Net Income | 130M | 190M | 253M | 102M | -46.3M | 247M | 370M | 454M | 142M | 197M | 15.3M |
| EPS | 0.36 | 0.49 | 0.63 | 0.25 | -0.12 | 0.62 | 0.86 | 1.05 | 0.33 | 0.46 | 0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 1.02B | 1.34B | 1.84B | 2.41B | 2.25B | 3.02B | 3.54B | 3.77B | 4.31B | 4.41B | 4.13B |
| Total Liabilities | 296M | 276M | 525M | 1.01B | 907M | 665M | 804M | 625M | 1.20B | 1.14B | 1.12B |
| Shareholders' Equity | 720M | 1.06B | 1.31B | 1.40B | 1.34B | 2.36B | 2.74B | 3.15B | 3.11B | 3.26B | 3.01B |
| Cash & Short-term Investments | 217M | 71.0M | 131M | 857M | 900M | 1.41B | 1.76B | 1.83B | 2.01B | 1.43B | 885M |
| Total Debt | 66.3M | 23.3M | 169M | 461M | 447M | 111M | 219M | 57.6M | 338M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 137M | 136M | 234M | 190M | 271M | 303M | 473M | 494M | 307M | -48.2M | - |
| Capital Expenditure | 13.9M | 45.3M | 80.9M | 159M | 155M | 152M | 190M | 177M | 207M | 142M | 152M |
| Free Cash Flow | 123M | 90.9M | 153M | 31.6M | 116M | 151M | 283M | 312M | 99.8M | -190M | -449M |
| Ratios | |||||||||||
| ROE | 18.1% | 17.9% | 19.3% | 7.2% | -3.4% | 10.5% | 13.5% | 14.4% | 4.6% | 6.0% | 0.5% |
| ROA | 12.8% | 14.2% | 13.8% | 4.2% | -2.1% | 8.2% | 10.4% | 12.0% | 3.3% | 4.5% | 0.4% |
| Net Profit Margin | 18.1% | 19.2% | 20.6% | 8.1% | -4.0% | 17.1% | 21.0% | 21.4% | 7.1% | 8.5% | 0.7% |
| Debt to Equity | 0.09x | 0.02x | 0.13x | 0.33x | 0.33x | 0.05x | 0.08x | 0.02x | 0.11x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SonoScape Medical Corp dividends
- Dividend yield
- 0.51%
- Forward dividend
- 0.18 CNY
- Payout ratio
- 23.9%
- Ex-dividend date
- Jun 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 47.2M | 0.11 | 23.9% |
| 2024 | CNY 144M | 0.34 | 101.4% |
| 2023 | CNY 82.7M | 0.19 | 18.2% |
| 2022 | CNY 53.5M | 0.12 | 14.5% |
| 2021 | CNY 5.54M | 0.01 | 2.2% |
| 2020 | CNY 10.5M | 0.03 | - |
| 2019 | CNY 26.0M | 0.07 | 25.6% |
| 2018 | CNY 21.7M | 0.05 | 8.6% |
| 2017 | CNY 15.6M | 0.04 | 8.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SonoScape Medical Corp
- Insiders 56.35%
- Institutions 8.61%
- Public & others 35.05%
- Shares outstanding 425M
- Free float 183M
SonoScape Medical Corp company profile
- Company name
- SonoScape Medical Corp
- Ticker
- 300633.SHE
- ISIN
- CNE100002P91
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,133
- Fiscal year end
- December
- Address
- Kaili Medical Building, Shenzhen, China, 518107
- Phone
- 86 755 2672 2890
- Website
- sonoscape.com
About SonoScape Medical Corp
SonoScape Medical Corp., together with its subsidiaries, engages in the research, development, production, and sale of medical diagnosis and treatment equipment in China and internationally. It offers ultrasound medical imaging products comprising trolley and portable color dopplers, B/W ultrasounds, and transducers; endoscopic diagnosis and treatment products consisting of image processors, light sources, gastroenterology and pulmonology products, endoscopic ultrasound, duodenoscopes, and peripheral equipment; minimally invasive surgery solutions, such as camera systems and flexible endoscopes; veterinary ultrasound and endoscopy solutions; and intravascular intervention products. The company also provides face-to-face and online training for ultrasound and endoscopy systems; technical and spare parts support; preventive maintenance, calibration, breakdown repair, and other field services; and upgrade services. In addition, it is involved in the software industry. SonoScape Medical Corp. was incorporated in 2002 and is headquartered in Shenzhen, China.
SonoScape Medical Corp management
7- Mr. Kunxiang WuGM & Director · born 1963
- Mr. Yuezuo LuoChief Financial Officer · born 1983
- Mr. Yibo HuangDeputy GM & Director · born 1966
- Nai Zhang FengDeputy GM & Director · born 1975
- Mr. Hao LiBoard Secretary & Deputy GM · born 1978
- Mr. Xiang LiDeputy General Manager · born 1984
- Tingting XuAccounting Supervisor